Panel rejects psychedelic drug MDMA as a PTSD treatment
washington — Federal health advisers voted Tuesday against a first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD, handing a potentially major setback to advocates who had hoped to win a landmark federal approval and bring the banned drugs into the medical mainstream. The panel of advisers to the Food and Drug Administration sided 10-1 against the overall benefits of MDMA when used to treat post-traumatic stress disorder. They cited flawed study data, questionable research conduct and significant drug risks, including the potential for heart problems, injury and abuse. "It seems like there are so many problems with the data — each one alone might be OK, but when you pile them on top of each other … there's just a lot of questions I would…